Dr. Reddy’s Laboratories Ltd (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has partnered with Bayer to distribute a second brand of the heart failure drug Vericiguat, named Gantra®, in India, aiming to improve treatment access for the large population suffering from chronic heart failure with reduced ejection fraction. Vericiguat represents a novel class of therapy that addresses a previously untargeted pathway in heart failure management, with the potential to reduce hospitalizations and cardiovascular deaths. The collaboration aligns with Dr. Reddy’s commitment to enhancing its chronic therapy portfolio and expanding the availability of innovative medicines in the Indian market.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
